Alteogen signs $365m Hybrozyme licensing deal with pharma company

Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology. The post Alteogen signs $365m Hybrozyme licensing deal with pharma company appeared first on Hospital Management .